Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Theravance Biopharma stock
Learn how to easily invest in Theravance Biopharma stock.
Theravance Biopharma is a biotechnology business based in the US. Theravance Biopharma shares (TBPH) are listed on the NASDAQ and all prices are listed in US Dollars. Theravance Biopharma employs 158 staff and has a trailing 12-month revenue of around $51.6 million.
How to buy Theravance Biopharma stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – TBPH. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Theravance Biopharma stock price (NASDAQ: TBPH)Use our graph to track the performance of TBPH stocks over time.
Theravance Biopharma shares at a glance
|Latest market close||$10.67|
|52-week range||$7.53 - $11.83|
|50-day moving average||$10.94|
|200-day moving average||$9.80|
|Wall St. target price||$12.56|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.02|
Buy Theravance Biopharma stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Theravance Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Theravance Biopharma price performance over time
|1 week (2023-01-20)||-3.83%|
|1 month (2022-12-28)||-4.48%|
|3 months (2022-10-28)||6.81%|
|6 months (2022-07-28)||20.43%|
|1 year (2022-01-27)||27.94%|
|2 years (2021-01-28)||-41.73%|
|3 years (2020-01-28)||27.2|
|5 years (2018-01-26)||28.98|
Theravance Biopharma financials
|Revenue TTM||$51.6 million|
|Gross profit TTM||$-138,346,000|
|Return on assets TTM||-10.81%|
|Return on equity TTM||-90.12%|
|Market capitalisation||$740.4 million|
TTM: trailing 12 months
Theravance Biopharma share dividends
We're not expecting Theravance Biopharma to pay a dividend over the next 12 months.
Theravance Biopharma share price volatility
Over the last 12 months, Theravance Biopharma's shares have ranged in value from as little as $7.53 up to $11.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theravance Biopharma's is 0.5309. This would suggest that Theravance Biopharma's shares are less volatile than average (for this exchange).
Theravance Biopharma overview
Theravance Biopharma, Inc. , a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc.
Theravance Biopharma in the news
Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets
11 Cheap Value Stocks to Buy According to Seth Klarman
Frequently asked questionsWhat percentage of Theravance Biopharma is owned by insiders or institutions?
Currently 11.196% of Theravance Biopharma shares are held by insiders and 98.473% by institutions. How many people work for Theravance Biopharma?
Latest data suggests 158 work at Theravance Biopharma. When does the fiscal year end for Theravance Biopharma?
Theravance Biopharma's fiscal year ends in December. Where is Theravance Biopharma based?
Theravance Biopharma's address is: Ugland House, George Town, Cayman Islands, KY1-1104 What is Theravance Biopharma's ISIN number?
Theravance Biopharma's international securities identification number is: KYG8807B1068 What is Theravance Biopharma's CUSIP number?
Theravance Biopharma's Committee on Uniform Securities Identification Procedures number is: G8807B106
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert